You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKinsey
Dow
Mallinckrodt
Colorcon

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Litigation Details for 3G Licensing, S.A. v. HTC Corporation (D. Del. 2017)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

3G Licensing, S.A. v. HTC Corporation (D. Del. 2017)

Docket   Start Trial Date Filed 2017-01-30
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand Plaintiff Referred To
Parties 3G LICENSING, S.A.; HTC AMERICA INC.; HTC CORPORATION; KONINKLIJKE KPN N.V.; ORANGE S.A.
Patents 10,041,934; 8,298,576; 8,420,650; 8,933,298; 8,933,302; 9,677,105; 9,700,564; 9,856,320; 9,896,424
Attorneys Alejandra C. Salinas; Alexander H. Lee; Alexandra White; Andres C. Healy; Brian E. Farnan; Bruce S. Yen; Hunter Vance; Jeff David; Jenna G. Farleigh; John W. Shaw; Jonas P. Herrell; Joseph J. Farnan , Jr.; Michael J. Farnan; Nathan Roger Hoeschen; Philip Ou; Radhesh Devendran; Rocco Magni; Yar R. Chaikovsky
Firms Farnan LLP; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in 3G Licensing, S.A. v. HTC Corporation
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .
Biologic Drugs cited in 3G Licensing, S.A. v. HTC Corporation

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for 3G Licensing, S.A. v. HTC Corporation (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
2020-05-14 424 Brief - Opening Brief in Support involved in patent licensing efforts for KPN as part of a patent pool. (See D.I. 75 ¶¶ 28, 32-35, 41-42). …effort to keep the ’662 Patent in the same case as the 3G Patents. (See D.I. 422 at 10-11). But doing so creates…matter and requested severance of the ’662 patent. (Ex. A at 10:24-12:17) (Tr.). The Court indicated that… severs the ‘662 patent for trial. KPN has requested an extension of deadlines by 10 weeks given its inability… Filed 05/14/20 Page 10 of 18 PageID #: 21328 KPN owns U.S. Patent Nos. 6,212,662 and 9,014,667 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Colorcon
McKesson
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.